Toursynbio is a technology company dedicated to AI-powered innovative drug discovery and development. Founded in 2023, the company brings together a multidisciplinary R&D team with expertise spanning artificial intelligence, computational biology, structural biology, and drug discovery.
Toursynbio is committed to building a next-generation Autonomous AI Biopharma Foundry, accelerating the development of an AI-native biopharmaceutical innovation ecosystem, and advancing autonomous intelligent models for biopharmaceutical R&D and their industrial applications.
Within six months, Toursynbio successfully progressed 16 antibody drug programs through PCC-stage validation, with encouraging results demonstrated in preclinical studies. Meanwhile, the company has achieved world-leading experimentally validated performance in traditionally challenging drug discovery targets, including GPCRs and intrinsically disordered regions (IDRs), demonstrating breakthrough technological capabilities and significant commercialization potential in AI-driven innovative drug discovery.
Scientific superintelligence agents integrate foundation models, domain-specific tools, autonomous reasoning, and experimental feedback. By connecting molecular design, experimental validation, and iterative optimization in one workflow, they accelerate scientific discovery and biopharmaceutical R&D.
Our integrated computational–experimental laboratory connects design with validation, creating a closed loop of testing, data feedback, and model iteration to accelerate candidate discovery and optimization.
Starting from target structures and functional requirements, our de novo design technology generates functional proteins with novel sequences and structures, providing new molecular solutions for complex and traditionally difficult-to-drug targets.
In the GEM × Adaptyv RBX1 Binder Design Competition 2026, TOURSYNBIO applied proprietary AI-driven protein design technologies to generate de novo binders against RBX1, a challenging cancer-related target.
Among approximately 43 participating teams worldwide, TOURSYNBIO achieved:
• 🏆 Global Runner-up (#2 worldwide)
• 🥇 #1 among Chinese participating teams
The representative binder deep-bear-clay achieved:
• Binding affinity (KD): 85 nM
• Hit rate: 28.6%
• 9 hits identified among 300 tested candidates
This achievement demonstrates TOURSYNBIO's capability in AI-powered de novo protein design and functional binder discovery.
Toursynbio is committed to accelerating R&D of scientific products through superintelligent technology, with applications in novel design of biological and material products.
Meet Our Partners→